

Strategies for Anticoagulation in Patients With Thrombocytopenia and Cancer-associated Thrombosis

NCT05255003

Status	RECRUITING
Phase	Phase 4
Sponsor	Tzu-Fei Wang
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (4)

- Adult patients (age ≥ 18) with active malignancy (malignancy diagnosed or treated within the previous 6 months, or progressive/relapsed);
- Objectively confirmed VTE within last 14 days for which therapeutic anticoagulation is planned;
- Thrombocytopenia with a platelet count < 50,000/uL from cancer therapy or malignancy itself;
- Able to provide written informed consent

Exclusion (9)

- Receipt of anticoagulant for index VTE with platelet count < 50,000/uL for > 72 hours;
- Superficial vein thrombosis only;
- Life expectancy < 1 month (as judged by the treating physicians);
- Creatinine clearance < 30 ml/min;
- Contraindication to LMWH such as a history of heparin induced thrombocytopenia;
- ... and 4 more (see full listing online)

Locations (4 total)

University of Alberta, Edmonton, Alberta, Canada
The Ottawa Hospital, Ottawa, Ontario, Canada
Niagara Health - St. Catharines Site, Saint Catharines, Ontario, Canada
... and 1 more locations